Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense

被引:166
作者
Basith, Shaherin [1 ]
Manavalan, Balachandran [2 ]
Yoo, Tae Hyeon [1 ]
Kim, Sang Geon [3 ,4 ]
Choi, Sangdun [1 ]
机构
[1] Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, South Korea
[2] Korea Inst Adv Study, Sch Computat Sci, Ctr In Silico Prot Sci, Seoul 130722, South Korea
[3] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[4] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea
基金
新加坡国家研究基金会;
关键词
Toll-like receptor; Antitumor; Tumorigenesis; Inflammation; Tumor immunotherapy; Proinflammatory cytokines; NF-KAPPA-B; PATTERN-RECOGNITION RECEPTORS; SQUAMOUS-CELL CARCINOMA; BLP25 LIPOSOME VACCINE; PROMOTES TUMOR-GROWTH; SEQUENCE VARIANTS; LUNG-CANCER; CPG-OLIGODEOXYNUCLEOTIDES; PATHOGEN RECOGNITION; INCREASED EXPRESSION;
D O I
10.1007/s12272-012-0802-7
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Toll-like receptors (TLRs) belong to a class of pattern-recognition receptors that play an important role in host defense against pathogens by recognizing a wide variety of pathogen-associated molecular patterns (PAMPs). Besides driving inflammatory responses, TLRs also regulate cell proliferation and survival by expanding useful immune cells and integrating inflammatory responses and tissue repair processes. TLR signaling, which is centrally involved in the initiation of both innate and adaptive immune responses, has been thought to be restricted to immune cells. However, recent studies have shown that functional TLRs are expressed not only on immune cells, but also on cancer cells, thus implicating a role of TLRs in tumor biology. Increasing bodies of evidence have suggested that TLRs act as a double-edged sword in cancer cells because uncontrolled TLR signaling provides a microenvironment that is necessary for tumor cells to proliferate and evade the immune response. Alternatively, TLRs can induce an antitumor immune response in order to inhibit tumor progression. In this review, we summarize the dual roles of TLRs in tumor cells and, more importantly, delve into the therapeutic potential of TLRs in the context of tumorigenesis.
引用
收藏
页码:1297 / 1316
页数:20
相关论文
共 150 条
  • [31] Masquerader: High mobility group box-1 and cancer
    Ellerman, Jessica E.
    Brown, Charles K.
    de Vera, Michael
    Zeh, Herbert J.
    Billiar, Timothy
    Rubartelli, Anna
    Lotze, Michael T.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (10) : 2836 - 2848
  • [32] Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors
    Fukata, Masayuki
    Chen, Anli
    Vamadevan, Arunan S.
    Cohen, Jason
    Breglio, Keith
    Krishnareddy, Suneeta
    Hsu, David
    Xu, Ruiliang
    Harpaz, Noam
    Dannenberg, Andrew J.
    Subbaramaiah, Kotha
    Cooper, Harry S.
    Itzkowitz, Steven H.
    Abreu, Maria T.
    [J]. GASTROENTEROLOGY, 2007, 133 (06) : 1869 - 1881
  • [33] Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help
    Garay, Ricardo P.
    Viens, Patrice
    Bauer, Jacques
    Normier, Gerard
    Bardou, Marc
    Jeannin, Jean-Francois
    Chiavaroli, Carlo
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 563 (1-3) : 1 - 17
  • [34] Unleashing the therapeutic potential of NOD-like receptors
    Geddes, Kaoru
    Magalhaes, Joao G.
    Girardin, Stephen E.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (06) : 465 - 479
  • [35] Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence
    Gonzalez-Reyes, Salome
    Fernandez, Jesus M.
    Gonzalez, Luis O.
    Aguirre, Alina
    Suarez, Aurelio
    Gonzalez, Jose M.
    Escaff, Safwan
    Vizoso, Francisco J.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (02) : 217 - 226
  • [36] Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis
    Gonzalez-Reyes, Salome
    Marin, Laura
    Gonzalez, Lucia
    Gonzalez, Luis O.
    del Casar, Jose M.
    Lamelas, Maria L.
    Gonzalez-Quintana, Jose M.
    Vizoso, Francisco J.
    [J]. BMC CANCER, 2010, 10
  • [37] Primary Leukocyte Screens for Innate Immune Agonists
    Goodchild, Amber
    Nopper, Nicole
    Craddock, Alexis
    Law, Tamara
    King, Andrew
    Fanning, Gregory
    Rivory, Laurent
    Passioura, Toby
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (06) : 723 - 730
  • [38] Cutting edge: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides
    Gorden, Keith K. B.
    Qiu, Xiaohong X.
    Binsfeld, Christine C. A.
    Vasilakos, John P.
    Alkan, Sefik S.
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 177 (10) : 6584 - 6587
  • [39] Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors
    Goto, Yasufumi
    Arigami, Takaaki
    Kitago, Minoru
    Nguyen, Sandy L.
    Narita, Norihiko
    Ferrone, Soldano
    Morton, Donald L.
    Irie, Reiko F.
    Hoon, Dave S. B.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2008, 7 (11) : 3642 - 3653
  • [40] Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression
    Grimm, Martin
    Kim, Mia
    Rosenwald, Andreas
    Heemann, Uwe
    Germer, Christoph-Thomas
    Waaga-Gasser, Ana Maria
    Gasser, Martin
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) : 2849 - 2857